Memo Therapeutics AG
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients (NCT05769582) | Memo Therapeutics AG | 2023-04-10 |
| Assess Safety, Tolerability and Pharmacokinetics of AntiBKV in Healthy Adult Volunteers. (NCT05358106) | Memo Therapeutics AG | 2022-05-09 |
| To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19. (NCT05351437) | Memo Therapeutics AG | 2022-04-26 |
Track Memo Therapeutics AG automatically
Every clearance here is in the API, with alerts when new ones post.